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Introduction 
Spinal cord injuries (SCI) are one of the most 
complex injuries to treat in the medical area. Due 
to the complexity of the spinal cord, the 
treatments are mostly palliative, used to prevent 
the progression of the injury, handle spasticity, 
deafferentation pain syndromes and 
dysautonomia
1
. Herein, we propose a cell-based 
approach, taking benefit of particular 
characteristics of adipose derived stem/stromal 
cells (hASC).  When compared to other stem cell 
sources, hASC present key advantages such as 
their immuno-modulatory properties, low 
immunogenicity, high cell yield per gram of 
processed tissue, and, their neural differentiation 
potential, which have been described
2
. In this 
project, we aimed to explore and validate 
procedures to differentiate hASC into cells of the 
neural lineage, through the use of xeno-free and 
therapeutic grade reagents along the entire cell 
manufacturing process. 
 
Materials and Methods 
Human ASC (hASC xeno-free, irisbiosciences, 
Portugal) were cultured in xeno-free media as 
control, or in neural induction media (Cell 
Therapy Systems, Life Technologies). Three 
culturing phases were tested: i) Expansion, for 
cell proliferation up to p2-3; ii) Pre-Induction, 
where cells were stimulated with 20ng/mL bFGF 
and 20ng/mL EGF and iii) Differentiation, where 
cells were cultured 10 days, triggered by brain 
derived neurotrophic factor (BDNF, 10ng/mL). 
Additionally, cells were cultured in presence or 
absence of poly-l-lysin/laminin coated surfaces. 
After pre-induction and differentiation phases, 
gene expression of neural markers were 
determined by qRT-PCR: bIII tubulin and 
neurofilament (NEFL) for early and mature 
neural differentiation, respectively; myelin basic 
protein (MBP) as an oligodendrocytic marker, 
and glial fibrillary acidic protein (GFAP) as 
astrocytic marker.  
Results 
When compared to expansion media, cells 
cultured in neural induction media proliferated 
less, and formed so-called neuro-spheres in non-
adherent plates. Yet, cells that remained in 
monolayer, demonstrated higher gene expression 
of neural markers. This was also observed for 
cells cultured in coated surfaces. At end of 
culture, NEFL was the mostly expressed marker, 
followed by MBP (Fig.1) 
 
Fig. 1 Gene expression of neural markers in 
differentiated cells relative to non-differentiated .  
 
Discussion and Conclusions 
With the developed procedure, yet to be 
validated, high up-regulation of neural lineage 
genes were determined after differentiation, 
relatively to non-differentiation control: 10-40x 
of βIII tubulin neuron marker; 60-540x of NEFL 
neuron marker and 7-295x of MBP oligo-
dendrocyte marker. No GFAP expression was 
detected suggesting that the conditions tested do 
not promote establishment of astrocytic cells. 
This data suggest that the tested protocol might 
become suitable for production of cells useful for 
SCI repair therapies. 
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